Yipinhong announced on January 5 that Guangzhou Yipinhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Supplement Application Approval Notice” for oseltamivir phosphate capsules approved and issued by the State Drug Administration. After review, the current application for this product complied with the relevant requirements for drug registration. It was agreed that the product would be increased by 30 mg and that a drug approval number would be issued. At the same time, the following related supplementary application matters were approved: 1. Change registration standards; 2. Change production process.

Yipinhong announced on January 5 that Guangzhou Yipinhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Supplement Application Approval Notice” for oseltamivir phosphate capsules approved and issued by the State Drug Administration. After review, the current application for this product complied with the relevant requirements for drug registration. It was agreed that the product would be increased by 30 mg and that a drug approval number would be issued. At the same time, the following related supplementary application matters were approved: 1. Change registration standards; 2. Change production process.